Patent ID: 7462599

Claim:
A method of inhibiting the conversion of N-terminal glutamic acid or glutamine residues to pyroglutamic acid residues of at least one substrate of glutaminyl cyclase in a mammalian subject comprising: administering to a mammalian subject in need thereof an inhibitor of glutaminyl cyclase (QC), or a pharmaceutically acceptable salt thereof; wherein the inhibitor of glutaminyl cyclase inhibits the conversion of N-terminal glutamic acid or glutamine residues to pyroglutamic acid residues of at least one substrate of glutaminyl cyclase selected from the group consisting of Glu 1 -ADan, Glu 1 -ABri, [Gln 3 ]Aβ(3-11)a, Aβ3-40/42, Aβ11-40/42, [Gln 3 ]Aβ3-40/42, [Gln 1 ]CCL 2, [Gln 1 ]CCL 7, [Gln 1 ]CCL 8, [Gln 1 ]CCL 16, [Gln 1 ]CCL 18, and [Gln 1 ]Fractalkine in the mammalian subject; and the mammalian subject is diagnosed with Familial British Dementia or Familial Danish Dementia.